Silke Gillessen joins Tom and Brian, who give their opinion on new data presented at the conference and it’s new ‘Take Home Message’ format. ...
The Uromigos: ASCO
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news from the ASCO annual meeting.
Advertisement
David McDermott discusses the adjuvant vs neoadjuvant trial and its wider implications for the genitourinary oncology field.
Dr. Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node-only first-line UC patients.
Dr. Laurence Albiges discusses this biomarker which may have predictive and prognostic capabilities for kidney cancer.
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of the KN426 and CLEAR trials.
Dr. Andrea Necchi describes the efficacy and toxicity of neoadjuvant sacituzumab govitecan in urothelial carcinoma.
Dr. Jonathan Rosenberg breaks down the data available for the bladder cohort from the DESTINY-PanTumor02 trial.
Dr. Alex Wyatt describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.
Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study for castration-resistant prostate cancer.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
Silke Gillessen, MD, PhD joins The Uromigos to discuss the genitourinary oncology highlights of ASCO 2023.
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial.
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.
We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for.
The Uromigos Episode 178: ASCO 2022 Germline Variants in Men of African Descent With Prostate Cancer
Veda Giri discusses germline variants among African American males and specific genes related to prostate cancer.Data from the ENZAMET trial reconfirms survival benefit with enzalutamide in mHSPC, but the role of docetaxel is uncertain.
Matt Galsky discusses research posters presented that cover the effects of HER2-targeting ADCs for urothelial cancer.
Nazli Dizman covers an update on the CBM588 probiotic strain and its phase II trial.
Amir Goldkorn, MD, discusses findings from a phase 2 bladder trial, responses to neoadjuvant chemotherapy, and more.
Robert Jones, MD, talks about the hypothesis for ATLANTIS, its specific trial results, and more.
Christopher W. Ryan, MD, shares long-awaited data about adjuvant everolimus in kidney cancer, the EVEREST trial, and results.
Silke Gillessen gives a safety update from this EORTC study focusing on fractures.
Chris Sweeney and Silke Gillessen give their opinion of recent data on radionuclides therapy in prostate cancer.
Dr. Kosj Yamoah of Moffitt Cancer Center describes the work he presented at ASCO 2021.
The Uromigos discuss an intriguing abstract that explores triplet therapy in metastatic hormone-sensitive prostate cancer.
Dr. Nizar Tannir and the Uromigos discuss the phase 3 trial of cabozantinib +/- a glutaminase inhibitor in refractory mRCC.
The Uromigos discuss a plenary presentation on adjuvant pembrolizumab versus placebo in high-risk resected RCC.
Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.
Matt Gowski takes a deeper dive into the phase 2 data of neoadjuvant chemo/nivolumab in muscle-invasive bladder cancer.
The Uromigos and Andrea Necchi have a wide-ranging discussion of 3 interesting neoadjuvant IO-based phase 2 trials.
Arjun Balar explains why, despite a negative trial, T cell stimulation plus checkpoint inhibition may warrant future study.
Mike Morris explains how radionucleotides and PSMA-based therapeutics impact metastatic castration-resistant prostate cancer.
The Uromigos and Monty Pal discuss data on microbiome modification's impact on immune-oncology clinical efficacy in mRCC.
Dr. Peter Black talks about his BCG refractory NMIBC presentation at ASCO 2020 and its implications for the field.
The Uromigos Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC With Jonathan Rosenberg
The Uromigos and Dr. Jonathan Rosenberg discuss everything you wanted to know about FGFR inhibition but were afraid to ask.Dr. Tian Zhang discusses 3 ASCO 2020 bladder cancer abstracts with immune therapy/targeted therapy combinations.
Dr. Kala Sridhar, Professor Tom Powles, and Dr. Brian Rini discuss the data presented at ASCO 2020.
Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal.
Joaquim Bellmunt explains why this trial was not successful and what it means for the field.
Thomas Hope is quizzed on the results of his study presented at ASCO 2020.
Mike Atkins describes the results of this study, which sheds light on the role of ipilimumab and nivolumab in this disease.
Betsy Plimack discusses the updated data from KEYNOTE 426 with a minimum of 23 months' follow up.
Mike Morris presents the findings in his prospective study.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.